Institute of Hematology & Blood Diseases Hospital, China
Adult Ph-negative ALL has inferior outcomes compared to childhood ALL. Pediatric-inspired regimens have improved survival in adolescent and young adult (AYA) patients. Venetoclax, a BCL-2 inhibitor, has shown preclinical sensitivity in Ph-negative ALL. Our center's previous IH-2022 regimen (a pediatric-inspired regimen combined with venetoclax protocol) showed promising efficacy and tolerability in adult patients.Immunotherapy is effective in ALL. This study aims to integrate immunotherapy into the pediatric-inspired backbone to optimize the regimen and improve survival outcomes.
Age
14–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed, previously untreated (except prednisone/hydroxyurea) Ph-negative ALL
Age ≥14 years, ≤60 years
ECOG performance status ≤2
Adequate organ function (liver, kidney, cardiac)
For patients of childbearing potential: use of effective contraception
Willing and able to provide informed consent
You may not be if
Burkitt leukemia/lymphoma
Acute leukemia of ambiguous lineage
Pregnancy or lactation
Severe uncontrolled active infection
History of pancreatitis
Uncontrolled diabetes (HbA1c \>7.5%)
Active gastrointestinal bleeding within 6 months
Arterial/venous thrombosis within 6 months
Known HIV positivity
Severe psychiatric illness hindering compliance
Any other condition deemed unsuitable by the investigator